To discover, create and safely deliver the next generation of immunotherapy products that help patients conquer their diseases.

Learn More

Percent of Cancer deaths in the US potentially treatable by immunotherapy drugs

70%

No current approval for immunotherapy

30%

Approved to treat

Learn More

Unfortunately, patients who are eligible to receive immunotherapy and similar to receiving conventional cancer therapies, will experience a poor rate, toxicities and off-target effects that are harmful to normal cells

Our mission is to unlock the immunotherapy promises through the discovery and validation of new disease targets.
Learn More

Publications

Chiriva-Internati, M., & Bot, A. (2015). A New Era in Cancer Immunotherapy: Discovering Novel Targets and Reprogramming the Immune System. International Reviews Of Immunology, 34(2), 101-103. doi:10.3109/08830185.2015.1015888 | View Publication »

Grizzi, F., Mirandola, L., Qehajaj, D., Cobos, E., Figueroa, J. A., & Chiriva-Internati, M. (2015). Cancer-Testis Antigens and Immunotherapy in the Light of Cancer Complexity. International Reviews Of Immunology, 34(2), 143-153. doi:10.3109/08830185.2015.1018418 | View Publication »

Stay Connected

Your Name (required)

Your Email (required)